ARS Pharmaceuticals Announces That It Will Be Launching The NeffyinSchools Program In January 2025; The Program Will Provide Eligible Public And Private K-12 Schools In The U.S. The Opportunity To Receive Two Cartons Of Neffy 2mg For Use In Emergency...
ARS Pharmaceuticals Announces That It Will Be Launching The NeffyinSchools Program In January 2025; The Program Will Provide Eligible Public And Private K-12 Schools In The U.S. The Opportunity To Receive Two Cartons Of Neffy 2mg For Use In Emergency...
Type 1 allergic reactions can be life-threatening, can happen in minutes, and can be caused by stinging and biting insects, foods, medication, exercise, or other unknown causes. Studies show that up to 18% of children with food allergies have had a reaction from accidentally eating food allergens while at school.1 In addition, 25% of severe and potentially life-threatening reactions (anaphylaxis) reported at schools happened in children with no previous diagnosis of food allergy.1 ARS Pharmaceuticals Announces That It Will Be Launching The NeffyinSchools Program In January 2025; The Program Will Provide Eligible Public And Private K-12 Schools In The U.S. The Opportunity To Receive Two Cartons Of Neffy 2mg For Use In Emergency Situations At No Cost To The School
ARS製藥公司宣佈將在2025年1月啓動NeffyinSchools計劃；該計劃將爲美國符合資格的公立和私立K-12學校提供兩個箱子（四個一次性劑量）的Neffy 2mg，以備緊急情況使用，學校無需承擔任何費用。
Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy (epinephrine nasal spray) 2mg for use in emergency treatment of allergic reactions including anaphylaxis
美國符合資格的公立和私立K-12學校將有資格獲得兩個免費的箱子（四個一次性劑量）的neffy（腎上腺素鼻用噴霧劑）2mg，以用於緊急情況下的過敏反應治療，包括過敏性休克。
Interested schools are encouraged to review applicable state laws and regulations to ensure neffy for undesignated use meets all requirements
有意參與的學校被鼓勵審查適用的州法律和規定，以確保用於無指定用途的neffy符合所有要求。
SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that it will be launching the neffyinSchools Program in January 2025. The program will provide eligible public and private K-12 schools in the U.S. the opportunity to receive two cartons (four single use doses) of neffy (epinephrine nasal spray) 2mg for use in emergency situations at no cost to the school. neffy 2mg was recently approved for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.) Participating schools will be eligible to receive replacement doses when the product is used or expires.
聖地亞哥，2024年12月4日（環球新聞）—— ARS製藥公司（納斯達克：SPRY），致力於幫助高風險患者和護理人員更好地保護自己免受可能導致過敏性休克的過敏反應，今天宣佈將於2025年1月啓動neffyinSchools計劃。該計劃將爲美國符合資格的公立和私立K-12學校提供兩個箱子（四個一次性劑量）的neffy（腎上腺素鼻用噴霧劑）2mg，以便在緊急情況下使用，學校無需承擔任何費用。neffy 2mg最近已獲得批准，用於治療體重≥30kg（66磅）的成人和兒童的I型過敏反應，包括過敏性休克。參與學校將有資格在產品使用或過期時獲得替換劑量。
Type 1 allergic reactions can be life-threatening, can happen in minutes, and can be caused by stinging and biting insects, foods, medication, exercise, or other unknown causes. Studies show that up to 18% of children with food allergies have had a reaction from accidentally eating food allergens while at school.1 In addition, 25% of severe and potentially life-threatening reactions (anaphylaxis) reported at schools happened in children with no previous diagnosis of food allergy.1
I型過敏反應可能危及生命，可能在幾分鐘內發生，原因包括被叮咬的昆蟲、食物、藥物、運動或其他未知原因。研究表明，最高可達18%的食物過敏兒童在學校因意外食用食物過敏原而出現反應。此外，報告顯示，在學校發生的25%的嚴重和潛在危及生命的反應（過敏性休克）發生在之前沒有食物過敏診斷的兒童身上。
